Pennsylvania-based electronic instruments manufacturer Ametek Inc., whose products are used by industrial and aerospace companies, announced Wednesday that it has acquired a privately held power management systems manufacturer for approximately $128 million, giving it a boost in the medical and life sciences sectors.
Auxilium Pharmaceuticals Inc. lost a patent infringement suit Wednesday alleging Upsher-Smith Laboratories Inc.'s efforts to create a testosterone gel for men infringed 10 patents related to Auxilium's Testim gel, when a Delaware federal judge ruled Upsher-Smith's formulation didn't infringe.
The product liability firm Bowman and Brooke LLP has opened an office in San Diego with two former Morris Polich & Purdy LLP attorneys who specialize in drug and medical device injury lawsuits.
The U.S. Food and Drug Administration said Wednesday it has reached a $1.25 million settlement with Advanced Sterilization Products and two of its executives over allegations that the company knowingly distributed products with inaccurately printed expiration dates to customers.
Armed with new authority to regulate compounding pharmacies, the U.S. Food and Drug Administration on Wednesday revived efforts to identify medicines that are especially hard for the specialty manufacturers to produce and ineligible for relaxed oversight.
The U.S. Food and Drug Administration on Wednesday revised its recommendations for how generic-drug makers can prove that their products are released into the human body in the same manner as brand-name counterparts, issuing high-level guidance covering an array of approaches.
A Florida federal judge on Tuesday denied Nestle Health Science-Pamlab's bid for a preliminary injunction to block Virtus Pharmaceuticals LLC from marketing a generic version of prescription medical foods, saying the suit is based on unfair competition claims and not harm to patients.
The U.S. Food and Drug Administration on Tuesday warned that hundreds of thousands of Philips Healthcare defibrillators may fail in an emergency, and urged consumers to take additional precautions while awaiting replacement devices.
North Sound Capital LLC and two other institutional funds have sued Merck & Co. Inc. and its subsidiary for allegedly misrepresenting a crucial clinical study for its anti-cholesterol agents Zetia and Vytorin, according to court documents made public in New Jersey federal court on Wednesday.
Health care and life sciences giant Getinge AB plans to offer €139.3 million ($189.3 million) for medical monitoring solutions company Pulsion Medical Systems SE, a deal that would complement Getinge's recently released glucose and lactate monitoring system, according to a Wednesday statement.
Abbott Laboratories Inc. has settled a false advertising case with New York state, agreeing to pay $25,000 and stop using commercials that show energized children who drink its vitamin-enhanced SideKicks beverages scoring goals against sluggish kids who do not consume the product.
General Motors Co. will shed the last of its stake in former lending unit Ally Financial Inc. in a placement worth $900 million, while Men's Wearhouse — itself on a buyout hunt — is closing in on a deal that would send its discount clothing unit to Sycamore Partners.
Global pharmaceutical company The Medicines Co. will pay up to $474 million to nab Rempex Pharmaceuticals Inc., a company that develops therapies to battle multidrug-resistant bacteria, according to a Wednesday statement.
Exela Pharma Sciences LLC and its subsidiaries asked a Delaware federal judge to reconsider a recent ruling that they infringed Cadence Pharmaceuticals Inc.’s patents by creating a generic version of injectable-painkiller Ofirmev, saying Monday that new evidence proved one of the patents invalid.
U.S. regulators who found shortcomings with Indian drugmaker Wockhardt Ltd.’s corrective measures to address purported manufacturing standard violations at two major facilities asked the embattled generics giant to outline plans to fix potential deficiencies at its facilities around the world, according to a letter made public Tuesday.
A Belgian appeals court has overturned a lower court's decision and ruled that nutrition company Herbalife International’s sales model is in full compliance with Belgian law, Herbalife said Tuesday.
AstraZeneca AB has successfully demonstrated that it is entitled to more than $76 million for Canada-based Apotex Corp. and Torpharm Inc.’s infringement of patents that protected the company's indigestion drug Prilosec, according to a New York federal judge’s ruling unsealed Tuesday.
New Jersey-based Immunomedics Inc. has sued the University of California and Temple University to protect the biopharmaceutical company's alleged rights over a valuable life sciences product that a scientist fomerly with an entity that licensed such assets to Immunomedics may have improperly transferred to UC San Francisco.
Irell & Manella LLP attorneys took aggressive steps to strike down a patent covering a prenatal DNA test licensed by Sequenom Inc. by citing a host of case law holding that natural phenomena and their discoveries cannot be patented to net a win for molecular diagnostics firm Ariosa Diagnostics Inc.
Drugmaker Lundbeck Inc.'s seizure medication Onfi may cause rare but potentially fatal skin reactions including toxic epidermal necrolysis, a condition characterized by the peeling away of skin cells, the U.S. Food and Drug Administration warned Tuesday.
There are several unique defenses, depending on the state, available to defendant pharmaceutical companies which arise from the discord between consumer protection statutes and prescription drugs, say Yvonene McKenzie and Gabriel Vidoni at Pepper Hamilton LLP.
What is the thinking as to whether leaky air conditioner cases warrant multidistrict litigation treatment? On Dec. 5, the Judicial Panel on Multidistrict Litigation heads to Vegas to find out. This will bring a temperature shift in more ways than one from the September hearing, where the panel considered a potential MDL proceeding arising from allegedly defective clothes dryers, says Alan Rothman of Kaye Scholer LLP.
In addition to continued headline-grabbing litigation involving pharmaceutical companies in the wake of PLIVA Inc. v. Mensing, 2013 brought a number of important cases informing everything from class certification questions and product labeling trends to False Claims Act liability and fracking disputes, say attorneys at Weil Gotshal & Manges LLP.
China's Food and Drug Administration recently announced changes to its Drug Registration Rules, which, while demonstrating the agency’s determination to foster innovation, may not achieve a balance between multinational drug companies and domestic competitors in its current shape, says Katherine Wang of Ropes & Gray LLP.
Five years ago, the Federal Trade Commission waded into the debate regarding the competition issues posed by “follow-on biologics.” Some three years after Congress provided a pathway for approval of such products, no follow-on biologic has been approved by the U.S. Food and Drug Administration. Now the FTC is revisiting the issue — particularly state restrictions, say attorneys with Wilson Sonsini Goodrich & Rosati.
Although the bones of the R&D tax credit have not changed substantially over time, there have been small revisions legislatively and further clarification provided by court rulings. The latest extension of the credit — in effect until Dec. 31, 2013 — includes changes around the rules for taxpayers under common control and rules for computing the credit when a portion of a trade or business changes hands, says Jacqueline Lee, tax director at Baker Tilly Virchow Krause LLP.
In many instances, the very businesses still facing time and budgetary constraints that hamper employee understanding of compliance must now add a new layer of comprehension in 2014. The stage is set for a banner enforcement year for regulatory bodies worldwide, says Veta Richardson, president and CEO of the Association of Corporate Counsel.
On Nov. 7, the Ninth Circuit largely upheld the U.S. Environmental Protection Agency's approach under the Federal Insecticide, Fungicide and Rodenticide Act in registering the first recognized nanopesticide. Despite a remand to resolve certain issues, the EPA and nano stakeholders have reason to be pleased, say Lynn Bergeson and Timothy Backstrom at Bergeson & Campbell PC.
A California federal court's recent decision in Ariosa Diagnostics Inc. v. Sequenom Inc. continues the trend of narrowing the scope of patent-eligible subject matter and also provides an important cue to the industry that patents involving diagnostic methods or DNA tests may come under increasing attack at the patent office or the courts on the basis that they do not qualify for patent protection under Section 101, says Imran Khaliq of Arent Fox LLP.
It is premature to call the ruling in Eli Lilly v. Huang a landmark decision — too many hurdles remain for multinational companies to become complacent about protection of trade secrets in China. But the country's new law allowing preliminary injunctions to stop infringement is an encouraging step forward, say Richard Grams and Allan Goldner of Benesch Friedlander Coplan & Aranoff LLP.